Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|June 1, 2018
Fujifilm Opens Collaboration Center
Author(s)Pharmaceutical Technology Editors
FUJIFILM Diosynth Biotechnologies opens Cambridge, MA center to promote collaboration with biotech companies.
Advertisement
In advance of the 2018 BIO convention in Boston (June 5–7), FUJIFILM Diosynth Biotechnologies announced on May 31, 2018 the opening of its Cambridge (MA) Collaboration Center, featuring an atrium with event and meeting spaces designed to facilitate biotech partnership and education.
“With partnering as a key theme of the BIO convention, Fujifilm is thrilled to reveal its new Cambridge Collaboration Center, a space that will encourage partnership between biopharma leaders in Boston and beyond,” said Steve Bagshaw, chief executive officer of FUJIFILM Diosynth Biotechnologies in a press statement. “As a center for biotech innovation, at BIO 2018 Fujifilm will showcase its gene-therapy manufacturing and development solutions, which are designed to meet the needs of our partners to quickly and reliably support the delivery of advanced therapies to patients.”
Bagshaw will moderate a session at the BIO event, Delivering on the Promise of Gene Therapy, that will explore the way gene therapies are transforming patients’ lives, the challenges and opportunities in gene therapy scientific discovery, and new approaches in delivering new types of medicines to patients.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement